Identification of a high risk gastric cancer group using serum pepsinogen after successful eradication of Helicobacter pylori

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 1, 2013, Pages 78-83

  Haneda, Masahira ^a   Kato, Mototsugu ^a   Ishigaki, Saori ^a   Suzuki, Mio ^a   Takahashi, Masakazu ^a   Nakagawa, Manabu ^a   Ono, Shouko ^a   Mori, Yasuaki ^a   Mabe, Katsuhiro ^a   Nakagawa, Shouichi ^a   Kudo, Takahiko ^a   Shimizu, Yuichi ^a   Asaka, Masahiko ^b  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Gastric cancer screening; Gastric carcinoma; Helicobacterpylori eradication; Pepsinogen I II

Indexed keywords

PEPSINOGEN; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHEMOLUMINESCENCE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HELICOBACTER PYLORI; HIGH RISK POPULATION; HUMAN; IMMUNOASSAY; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; STOMACH CANCER;

EID: 84871649190     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07285.x     Document Type: Article

References (34)

1. Correa P, Haenszel W, Cuello C etal. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res. 1990; 50: 4737-4740.
2. Siurala M, Varis K, Wiljasalo M. Studies of patients with atrophic gastritis: a 10-15-year follow-up. Scand. J. Gastroenterol. 1966; 1: 40-48.
3. Svendsen JH, Dahl C, Sevendsen LB, Christiansen PM. Gastric cancer risk in achlorhydric patients. A long-term follow-up study. Scand. J. Gastroenterol. 1986; 21: 16-20.
4. Uemura N, Okamoto S, Yamamoto S etal. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001; 345: 784-789.
5. Cassaro M, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM. Topographic patterns of intestinal metaplasia and gastric cancer. Am. J. Gastroenterol. 2000; 95: 1431-1438.
6. Sipponen P, Stolte M. Clinical impact of routine biopsies of the gastric antrum and body. Endoscopy 1997; 29: 671-678.
7. Rugge M, Meggio A, Pennelli G etal. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007; 56: 631-636.
8. Faraji EI, Frank BB. Multifocal atrophic gastritis and gastric carcinoma. Gastroenterol. Clin. North Am. 2002; 31: 499-516.
9. Mario F, Cavallaro LG. Non-invasive tests in gastric disease. Dig. Liver Dis. 2008; 40: 523-530.
10. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am. J. Gastroenterol. 2003; 98: 735-739.
11. Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999; 44: 693-697.
12. Varis K, Sipponen P, Laxen F etal. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. Scand. J. Gastroenterol. 2000; 35: 950-956.
13. Broutet N, Plebani M, Sakarovitch C, Sipponen P. Megraud F and the Eurohepygast Study Group. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br. J. Cancer 2003; 88: 1239-1247.
14. Samloff IM. Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology 1971; 61: 185-188.
15. Samloff IM, Liebman WM. Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology 1973; 65: 36-42.
16. Miki K, Ichinose M, Shimizu A etal. Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol. Jpn 1987; 22: 133-141.
17. Borch K, Axelsson CK, Halgreen H, Damkjaer N, Ledin T, Szesci PB. The ratio of pepsinogen A to pepsinogen C: a sensitive test for atrophic gastritis. Scand. J. Gastroenterol. 1989; 24: 870-876.
18. Watabe H, Mitsushima T, Yamaji Y etal. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005; 54: 764-768.
19. Oishi Y, Kiyohara Y, Kubo M etal. The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am. J. Epidemiol. 2006; 163: 629-637.
20. Yanaoka K, Oka M, Mukoubayashi C etal. Cancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol. Biomarkers Prev. 2008; 17: 838-845.
21. Yoshihara M, Hiyama T, Yoshida S etal. Reduction in gastric cancer mortality by screening based on serum pepsinogen concentration: a case-control study. Scand. J. Gastroenterol. 2007; 42: 760-764.
22. Sasazuki S, Inoue M, Iwasaki M etal. Effect of Helicobacter pylori infection combined with CagA and pepsinogen status on gastric cancer development among Japanese men and women; a nested case-control study. Cancer Epidemiol. Biomarkers Prev. 2006; 15: 1341-1347.
23. Ohata H, Kitauchi S, Yoshimura N etal. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int. J. Cancer 2004; 109: 138-143.
24. Biemond I, Rieu PNMA, Jansen JBMJ, Joosten HJM, Lamers CBHW etal. Prospective study of the effect of gastrectomy with and without bile reflux on serum pepsinogens. Digestion 1989; 44: 124-130.
25. Peetsalu A, Tamm A, Harkonen M etal. The effect of vagotomy and antrectomy on serum pepsinogens 1 and 2. Scand. J. Gastroenterol. 1990; 25: 455-461.
26. Nakahama H, Tanaka Y, Shirai D etal. Elevated serum pepsinogens in chronic renal failure patients. Nephron 1995; 70: 211-216.
27. Shirai N, Furuta T, Sugimoto M etal. Serum pepsinogens as an early diagnostic marker of H. pylori eradication. Hepatogastroenterology 2008; 55: 486-490.
28. Hunter FM, Correa P, Fontham E etal. Serum pepsinogens as an early diagnostic markers of response to therapy for Helicobacter pylori gastritis. Dig. Dis. Sci. 1993; 38: 2081-2086.
29. Pérez-Paramo M, Albillos A, Calleja JL etal. Changes in gastrin and serum pepsinogens in monitoring of Helicobacter pylori response to therapy. Dig. Dis. Sci. 1997; 42: 1734-1740.
30. Ito M, Yoshihara M, Takata S etal. Serum screening for detection of the high-risk group for early-stage diffuse type gastric cancer in Japanese. Gastroenterology 2011 (in press).
31. Ito M. Actual medical practice and challenge of Helicobacter pylori in the metropolitan area. Helicobacter Res. 2010; 14: 314-318. (In Japanese).
32. Kato M, Asaka M, Ono S etal. Eradication of Helicobacter pylori for primary gastric cancer and secondary gastric cancer after EMR. J. Gastroenterol. 2007; 42: S16-20.
33. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992; 52: 6735-6740.
34. Palli D, Masala G, Del Giudice G etal. CagA+ Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study. Int. J. Cancer 2007; 120: 859-867.